Suven Life Sciences, a biopharmaceutical company, today said Wednesday the company has received two product patent grants corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases. It has secured one product patent from Europe (2758394) and another product patent from Hong kong (1173140).

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of sixteen granted patents from Europe and seventeen product patents from Hong Kong. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,'' says Venkat Jasti, CEO of Suven.

Shares of the company gained Rs 13.7, or 4.86%, to trade at  Rs 295.85.  The total volume of shares traded  was  197,701 at the BSE (10.46 a.m., Wednesday).